12.07.2015 Views

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Case 1:09-cv-04665-<strong>DL</strong>C Document 49-2 Filed 03/30/2010 Page 5 of 45extent Paragraph 15 states conclusions of law, no response is required. Except as expresslyadmitted above, Teva denies the allegations in Paragraph 15.16. Upon information and belief, Teva admits that the ‘404 patent, if valid andenforceable, expires on June 19, 2016. Teva further admits that the ‘404 patent lists on its face asan assignee Takeda Chemical Industries, Ltd. Except as expressly admitted above, Teva denies theallegations in Paragraph 16.17. United States Patent No. 6,166,043 (“the ‘043 patent”) speaks for itself. Tevaadmits that the ‘043 patent, entitled “Pharmaceutical Composition,” lists on its face an issue date ofDecember 26, 2000 and lists on its face as inventors Hitoshi Ikeda, Takashi Sohda and HiroyukiOdaka, but specifically denies that the patent was duly issued. Teva further admits that the ‘043patent lists on its face as an assignee Takeda Chemical Industries, Ltd. Teva further admits thatwhat purports to be a copy of the ‘043 patent is attached to the Complaint as Exhibit C. To theextent Paragraph 17 states conclusions of law, no response is required. Except as expresslyadmitted above, Teva denies the allegations in Paragraph 17.18. Upon information and belief, Teva admits that the ‘043 patent, if valid andenforceable, expires on June 19, 2016. Teva further admits that the ‘043 patent lists on its face asan assignee Takeda Chemical Industries, Ltd. Except as expressly admitted above, Teva denies theallegations in Paragraph 18.19. United States Patent No. 6,172,090 (“the ‘090 patent”) speaks for itself. Tevaadmits that the ‘090 patent, entitled “Pharmaceutical Composition,” lists on its face an issue date ofJanuary 9, 2001 and lists on its face as inventors Hitoshi Ikeda, Takashi Sohda and HiroyukiOdaka, but specifically denies that the patent was duly issued. Teva further admits that the ‘090patent lists on its face as an assignee Takeda Chemical Industries, Ltd. Teva further admits that9067383.14

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!